AstraZeneca Halts Lung Cancer Bispecific Trial Amid Mixed Pipeline Updates

AZN discontinued the Phase 3 eVOLVE-Lung02 trial of volrustomig after an independent data monitoring committee concluded the bispecific antibody was unlikely to meet either primary endpoint, progression-free survival or overall survival. The trial tested volrustomig with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer in patients with PD-L1 expression below 50%, measured against Merck's Keytruda plus chemotherapy.

Losing to Keytruda in first-line NSCLC is the specific way this setback matters. The comparator is the standard of care in the largest oncology market, and a bispecific that cannot clear it there loses the indication that justified its late-stage spend. The shares moved little on the news, which suggests the market had already discounted the asset rather than that the readout was immaterial.

The same period produced two positive late-stage lung cancer readouts. The Tagrisso and Orpathys combination met its goals, and the Daiichi Sankyo-partnered Enhertu showed a statistically significant and clinically meaningful improvement in progression-free survival as a first-line treatment for HER2-mutant non-squamous NSCLC in the DESTINY-Lung04 Phase 3 trial. Both build on approved, revenue-generating franchises.

That contrast is the real story of the pipeline right now: the marketed oncology assets keep extending into new lines and indications, while the novel modality intended to succeed them has stumbled. It shifts more of the medium-term growth burden onto label expansions of drugs already carrying the top line.

What to watch: whether volrustomig continues in other tumor types or is discontinued outright, regulatory filings following the DESTINY-Lung04 result, and how management reallocates the freed development spend at the next pipeline update.

Related Stocks

• AZN